原发性血小板增多症患者诊断时附加突变与治疗反应的关系
这项回顾性研究分析了121例原发性血小板增多症患者的分子特征,其中86例接受羟基脲一线治疗、35例接受聚乙二醇干扰素一线治疗。诊断时存在至少1个附加突变与未达完全缓解相关(HR 0.65,P=0.038),聚乙二醇干扰素治疗与更高的完全缓解率相关(HR 2.00,P=0.002)。
要点
- 诊断时≥1个附加突变与未达完全缓解相关(HR 0.65,P=0.038)。
- 聚乙二醇干扰素治疗与更高完全缓解相关(HR 2.00,P=0.002)。
- 附加突变数量与血液学进展相关(P<0.0001)。
核心结论
- 诊断时存在至少1个附加突变与未达完全缓解及血液学演变风险增加相关。
研究设计与样本
- 回顾性研究,分析121例原发性血小板增多症患者的分子特征,其中86例接受羟基脲一线治疗、35例接受聚乙二醇干扰素一线治疗。
主要发现
- 62例患者(51%)在诊断时存在至少1个附加突变。
- 治疗12个月时,75例(62%)达完全缓解,37例(31%)达部分缓解,7例(6%)无缓解。
- 诊断时存在至少1个附加突变与未达完全缓解相关(HR 0.65,P=0.038)。
- 聚乙二醇干扰素治疗与更高完全缓解相关(HR 2.00,P=0.002)。
- 诊断时附加突变数量与血液学进展相关(P<0.0001);接受聚乙二醇干扰素治疗者无进展为骨髓纤维化,而接受羟基脲治疗者中16/86例(19%)发生继发性骨髓纤维化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with essential thrombocythemia (ET) have a chronic evolution with a risk of hematologic transformation associated with a dismal outcome. Because patients with resistance or intolerance have adverse prognosis, it is important to identify which patient will respond to first-line treatment. We, therefore, aim to describe the association between additional mutations and response to first-line treatment in patients with ET. In this retrospective study, we analyzed the molecular landscape of 121 ET patients first-line treated with hydroxyurea (HU; n = 86) or pegylated interferon (peg-IFN; n = 35). Patients undergoing peg-IFN therapy were younger and had higher proportion of low and very low risk of thrombosis recurrence. A total of 62 patients (51%) had ≥1 additional mutations at diagnosis. At 12 months of treatment, 75 patients (62%) achieved complete response (CR), 37 (31%) partial response, and 7 (6%) no response. The presence of at least 1 additional mutation at diagnosis was associated with not achieving CR (hazard ratio [HR], 0.65; P = .038), whereas treatment with peg-IFN was associated with higher CR (HR, 2.00; P = .002). The number of additional mutations at diagnosis was associated with hematologic progressions (P < .0001). None of the patients receiving peg-IFN therapy progressed to myelofibrosis, whereas 16 of 86 patients (19%) treated with HU developed secondary myelofibrosis. In conclusion, our results suggest that the presence of at least 1 additional mutation at diagnosis is associated with failure to achieve CR and also with an increased risk of hematologic evolution.
引用
- Mosnier C, Bellal S, Cottin L, et al. Relationship between additional mutations at diagnosis and treatment response in patients with essential thrombocythemia. Blood Adv. 2025. PMID: 39820709. doi:10.1182/bloodadvances.2024014791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。